Idorsia Paves the Way Towards Its First Drug Approval: Daridorexant in Insomnia
The Swiss company Idorsia, one of the rising stars of the Swiss biotech scene and member of our Biotech Investments Model Portfolio, announces positive results for the second of two identical twin trials with its drug candidate Daridorexant in insomnia. This represents a major step forward towards a first drug approval by healthcare authorities worldwide. Idorsia’s stock reacts positively and continues its trend upwards.
Idorsia plans to file for a marketing approval for its potential next-generation insomnia drug Daridorexant at the end of the year. Overall, the results of the second phase 3 clinical trial are consistent with the ones observed for the first trial.
In the second study, Daridorexant at the higher 25 mg significantly improved sleep maintenance both at month 1 and 3, indicating that the efficacy of the drug is maintained over time. The effect on sleep onset and daytime functioning were also consistent with the ones seen in the first study but failed to reach statistical significance.
Daridorexant was well tolerated which is particularly important, given the fact that other insomnia drugs can be associated with dangerous adverse events. This might represent a competitive advantage over other drugs on the market.
Biotech Investments remains highly confident for Idorsia which is a long-term member of our Biotech Investments Model Portfolio.
The full press release of Idorsia can be found here.